Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

Summary

A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA 1241 in subjects with presumed non-alcoholic steatohepatitis (NASH).

Timeline

Start

2023-09-14

Primary completion

2024-10-24

Completion

2024-10-30

Outcome

Met primary endpoint

release “1차 평가변수와 2차 평가변수를 달성한 DA-1241 글로벌 임상 2상 탑라인 데이터 결과는 DA-1241이 MASH 치료제로서의 잠재력을 입증한 성과다” donga-st.com ↗

Drugs

Indications